Inactive Instrument

Xbrane Biopharma AB Share Price Nasdaq Stockholm

Equities

Biotechnology & Medical Research

End-of-day quote Nasdaq Stockholm
- SEK - Intraday chart for Xbrane Biopharma AB
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 344M 31.75M 2.65B Sales 2025 * 680M 62.87M 5.25B Capitalization 311M 28.76M 2.4B
Net income 2024 * -186M -17.19M -1.43B Net income 2025 * 104M 9.61M 802M EV / Sales 2024 * 0.82 x
Net cash position 2024 * 28.17M 2.6M 217M Net Debt 2025 * 116M 10.7M 893M EV / Sales 2025 * 0.63 x
P/E ratio 2024 *
-1.51 x
P/E ratio 2025 *
4.25 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 89.26%
More Fundamentals * Assessed data

Latest transcript on Xbrane Biopharma AB

Managers TitleAgeSince
Chief Executive Officer 44 01/15/01
Director of Finance/CFO 63 11/21/11
Chief Tech/Sci/R&D Officer 42 09/17/09
Members of the board TitleAgeSince
Director/Board Member 67 01/15/01
Director/Board Member 70 01/15/01
Director/Board Member 53 01/20/01
More insiders
Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.
Calendar
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW